What Ails the FDA? Payola – Marcia Angell Boston Globe Thu, 10 Mar 2005 The Boston Globe reports that the FDA is scrambling to put out one drug crisis after another, doing a poor job in both its areas of responsibility: medicine and food. FDA acting chief, Lester Crawford, cancelled…
FDA Panel Poses Pointed Questions to Drug Makers Over Risks of Painkillers – NYT Thu, 17 Feb 200 A three day public advisory panel hearing which is overflowing with attendees from around the world, is an investigation of the conduct of pharmaceutical company giants and the FDA. The hearing began…
THE NEW YORK TIMES February 12, 2005 Drug Regulators Are Trying to Quash Study, Senator Says By GARDINER HARRIS WASHINGTON, Feb. 11 – The tension and intrigue surrounding a crucial federal drug advisory committee meeting next week, already high, reached a boil on Friday when Senator Charles E. Grassley charged…
NIH to Ban Consulting Deals With Drug Firms – LAT / NYT Tue, 1 Feb 2005 Thanks to the investigative reports by David Willman in the Los Angeles Times, shedding light on secret financial ties by sernior scientists at the National Instiutes of Health, the public gained insight into the…
What’s a Patient to Think? Prescription for Confusion – NY Times Editorial Tue, 28 Dec 2004 At long last, The New York Times has validated the well-placed anger and frustration that patients feel at having their trust in medicine and the nation’s oversight agents betrayed: “Now I just don’t trust…
FDA Chief Counsel, Daniel Troy, Resigned Wed, 17 Nov 2004 FDA’s chief counsel, Daniel Troy, has resigned! This is good news for consumers. Troy was the symbol of what is rotten at the FDA: the pharmaceutical industry’s influence has ensured that business interests take precedence over public safety. Industry-influenced advisory…
Complaint to FDA: Pfizer Failed to Disclose Zoloft Suicide Risk in NYT Adverstisement Mon, 1 Nov 2004 ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Tel. 212-595-8974 142 West End Ave. Suite 28P Fax: 212-595-9086 New York, NY 10023 www.ahrp.org November 1, 2004 Thomas W. Abrams Director Office…
FDA Protects Pfizer: Removes Advisory Panelist for Citing Evidence Bextra Similar to Vioxx – WSJ Fri, 12 Nov 2004 Even as the Vioxx casualties are still being counted, even as FDA’s conduct is under Congressional investigation, the FDA office of new drugs has taken action to obstruct evidence-based safety evaluation…
Pfizer Zoloft Warnings to Canadian Doctors Contrast to US – FDA Caves In to Pharma lobbying Thu, 10 Feb 2005 The FDA has, once again, quietly colluded with industry, compromising the safety of children’s lives to maintain drug manufacturers’ cash flow. After two FDA advisory committee hearings (Feb 2-3 and…
Govt Prozac study Recommends MANDATORY Screening & Drugs – “Overdosed America”_OpEd NYT Sun, 19 Sep 2004 FDA’s Review of Safety & Efficacy Concerns in Anti-Depressant Use by Children is the subject of a second Congressional hearing by the House Energy & Commerce Subcommittee on Oversight / Investigations on September 23,…
18% decrease SSRI use in Youth – NYT / Suicide Risk Not New – Globe / Prozac no different Tue, 21 Sep 2004 The FDA failed to stop drug manufacturers from flooding the air waves and the scientific literature with false and scientifically invalid claims-based on partial data. “The FDA…
AHRP Press Briefing September 14, 2004 Antidepressants and Suicide-Related Risks for Children Scientists’ Presentations at AHRP Press Briefing in Conjunction with FDA Hearings: Peter Mansfield, MD, University of Adelaide (Australia), Director of Healthy Skepticism discussed the illusion of potency in light of the meta-analyses in the British Medical Journal (which…
